SI1835937T1 - Sestavki in postopki za zdravljenje virusne infekcije - Google Patents
Sestavki in postopki za zdravljenje virusne infekcijeInfo
- Publication number
- SI1835937T1 SI1835937T1 SI200631360T SI200631360T SI1835937T1 SI 1835937 T1 SI1835937 T1 SI 1835937T1 SI 200631360 T SI200631360 T SI 200631360T SI 200631360 T SI200631360 T SI 200631360T SI 1835937 T1 SI1835937 T1 SI 1835937T1
- Authority
- SI
- Slovenia
- Prior art keywords
- methods
- treating viral
- compositions
- viral infection
- receptors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200500027 | 2005-01-06 | ||
EP06700714A EP1835937B1 (en) | 2005-01-06 | 2006-01-06 | Compositions and methods for treating viral infection |
PCT/EP2006/050071 WO2006072624A2 (en) | 2005-01-06 | 2006-01-06 | Compositions and methods for treating viral infection |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1835937T1 true SI1835937T1 (sl) | 2012-08-31 |
Family
ID=36593628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200631360T SI1835937T1 (sl) | 2005-01-06 | 2006-01-06 | Sestavki in postopki za zdravljenje virusne infekcije |
Country Status (11)
Country | Link |
---|---|
US (2) | US8551483B2 (sl) |
EP (1) | EP1835937B1 (sl) |
JP (1) | JP5154949B2 (sl) |
AT (1) | ATE552852T1 (sl) |
CY (1) | CY1113182T1 (sl) |
DK (1) | DK1835937T3 (sl) |
ES (1) | ES2384466T3 (sl) |
PL (1) | PL1835937T3 (sl) |
PT (1) | PT1835937E (sl) |
SI (1) | SI1835937T1 (sl) |
WO (1) | WO2006072624A2 (sl) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090191213A9 (en) * | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
MXPA05013923A (es) | 2003-07-02 | 2006-08-11 | Univ Genova | Anticuerpos nk receptores de pan-kir2dl y su utilizacion en diagnostico y terapia. |
WO2006003179A2 (en) * | 2004-07-01 | 2006-01-12 | Novo Nordisk A/S | Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US20110280849A1 (en) * | 2010-03-26 | 2011-11-17 | Anthrogenesis Corporation | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
CA2837184C (en) * | 2011-05-25 | 2021-09-21 | Innate Pharma, S.A. | Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders |
WO2014189138A1 (ja) * | 2013-05-23 | 2014-11-27 | Idacセラノスティクス株式会社 | 免疫不全ウイルス感染の治療又は予防剤 |
US9782476B2 (en) | 2013-09-06 | 2017-10-10 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
EP3149036A4 (en) | 2014-05-27 | 2017-12-27 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
KR20170005142A (ko) | 2014-05-27 | 2017-01-11 | 아카데미아 시니카 | 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법 |
EP3149037A4 (en) | 2014-05-27 | 2018-01-10 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
JP7063538B2 (ja) | 2014-05-28 | 2022-05-09 | アカデミア シニカ | 抗TNFα糖操作抗体群およびその使用 |
WO2016031936A1 (ja) * | 2014-08-29 | 2016-03-03 | 国立大学法人北海道大学 | Kir2ds1に対するモノクローナル抗体 |
WO2017159088A1 (ja) * | 2016-03-16 | 2017-09-21 | 国立大学法人京都大学 | 移植用培養細胞または培養組織の調製方法 |
US10858431B2 (en) * | 2016-06-30 | 2020-12-08 | Trellis Bioscience, Llc | Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling |
CA3034057A1 (en) | 2016-08-22 | 2018-03-01 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
CN109833480B (zh) * | 2019-03-22 | 2021-09-07 | 中国科学院上海巴斯德研究所 | 靶向nk细胞免疫检查点治疗感染性疾病的方法 |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
CA3184366A1 (en) | 2020-06-29 | 2022-01-06 | Darby Rye Schmidt | Viruses engineered to promote thanotransmission and their use in treating cancer |
EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5660827A (en) | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
US5539094A (en) | 1993-11-12 | 1996-07-23 | La Jolla Cancer Research Foundation | DNA encoding Bcl-2-associated proteins |
US5583034A (en) | 1994-02-22 | 1996-12-10 | La Jolla Institute For Allergy And Immunology | Enhancement of adoptosis using antisense oligonucleotides |
US5808028A (en) | 1994-05-24 | 1998-09-15 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clone of a P58 receptor protein and uses thereof |
CA2372053C (en) | 1999-04-28 | 2008-09-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
KR100419555B1 (ko) | 2000-05-29 | 2004-02-19 | 주식회사유한양행 | 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자 |
MXPA05013923A (es) | 2003-07-02 | 2006-08-11 | Univ Genova | Anticuerpos nk receptores de pan-kir2dl y su utilizacion en diagnostico y terapia. |
BRPI0412890B8 (pt) * | 2003-07-24 | 2021-05-25 | Innate Pharma | método de selecionar um anticorpo anti kir2dl1 ou fragmento de anticorpo de ligação de antígeno |
-
2006
- 2006-01-06 WO PCT/EP2006/050071 patent/WO2006072624A2/en active Application Filing
- 2006-01-06 SI SI200631360T patent/SI1835937T1/sl unknown
- 2006-01-06 US US11/813,399 patent/US8551483B2/en active Active
- 2006-01-06 AT AT06700714T patent/ATE552852T1/de active
- 2006-01-06 JP JP2007549894A patent/JP5154949B2/ja active Active
- 2006-01-06 EP EP06700714A patent/EP1835937B1/en active Active
- 2006-01-06 DK DK06700714.6T patent/DK1835937T3/da active
- 2006-01-06 PL PL06700714T patent/PL1835937T3/pl unknown
- 2006-01-06 ES ES06700714T patent/ES2384466T3/es active Active
- 2006-01-06 PT PT06700714T patent/PT1835937E/pt unknown
-
2012
- 2012-06-29 CY CY20121100586T patent/CY1113182T1/el unknown
-
2013
- 2013-10-01 US US14/043,402 patent/US9333255B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9333255B2 (en) | 2016-05-10 |
US20090035305A1 (en) | 2009-02-05 |
JP5154949B2 (ja) | 2013-02-27 |
WO2006072624A3 (en) | 2006-11-16 |
CY1113182T1 (el) | 2016-04-13 |
ES2384466T3 (es) | 2012-07-05 |
US20140023646A1 (en) | 2014-01-23 |
JP2008526812A (ja) | 2008-07-24 |
EP1835937A2 (en) | 2007-09-26 |
WO2006072624A2 (en) | 2006-07-13 |
US8551483B2 (en) | 2013-10-08 |
EP1835937B1 (en) | 2012-04-11 |
ATE552852T1 (de) | 2012-04-15 |
DK1835937T3 (da) | 2012-07-23 |
PT1835937E (pt) | 2012-06-25 |
PL1835937T3 (pl) | 2012-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI1835937T1 (sl) | Sestavki in postopki za zdravljenje virusne infekcije | |
NO341586B1 (no) | Fremgangsmåte for valg av et anti-naturlig drepe cellereseptor (NKR) antistoff | |
DK1578936T3 (da) | Humane anti-IFN-gamma-neutraliserende antistoffer som selektive inhibitorer af IFN-gamma-vejen | |
BRPI0606790A2 (pt) | anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna. | |
WO2006110814A3 (en) | Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents | |
BR0212469A (pt) | Método para multiplicação de vìrus em cultura de célula | |
WO2008085562A3 (en) | Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies | |
MY141025A (en) | Dose forms | |
EA201000424A1 (ru) | Антитела к il-23 | |
ATE503769T1 (de) | Antikörper gegen das humane cytomegalie-virus (hcmv) | |
WO2010034670A3 (en) | Host cell kinases as targets for antiviral therapies against hcv infection | |
NO20064547L (no) | Fremgangsmater for behandling av HIV infeksjon | |
WO2004113275A3 (en) | Methods and compositions for treating amyloid-related diseases | |
IL187321A (en) | Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation | |
DE602006019977D1 (de) | Therapie mit anti-cd4-antikörpern und bestrahlung | |
NO20070854L (no) | Humane monoklonale antistoffer mot humant IL-4. | |
EA202091974A1 (ru) | Связывающие bcma антитела и их применение | |
WO2002092013A3 (en) | Methods for treating liver disease and liver damage with growth hormone and foxm1b | |
WO2006116185A3 (en) | Methods for the treatment of multiple myeloma | |
CL2007002370A1 (es) | Conjugado que consta de un anticuerpo anti-ccr5 y uno o mas peptidos antifusogenicos; composicion farmaceutica que lo comprende; metodo de preparacion; y su uso para tratar infecciones virales. | |
WO2006055404A3 (en) | Compounds for targeting mechanisms implicated in the progression of stroke | |
WO2005110391A3 (en) | Compounds for treating human papillomavirus | |
GB0220257D0 (en) | Vaccine | |
WO2002011549A3 (en) | Treatment of mycobacterial infection | |
WO2023159061A3 (en) | Human monoclonal antibodies targeting the s2 subunit of the sars-cov-2 spike protein |